Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

259 results about "Glycated hemoglobin" patented technology

<ul><li>Normal: HbA1c below 5.7%.</li><li>Prediabetes: HbA1c between 5.7% and 6.4.</li><li>Diabetes: HbA1c of 6.5% or higher.</li><li>If diabetic, the American Diabetes Association recommends keeping HbA1c levels below 7%.</li><li>The test is not used to diagnose diabetes in pregnant women (gestational diabetes) or children.</li><li>Further, the test may show less accurate results in people with blood disorders such as anemia.</li><li>Alternative tests such as glycated albumin or glycated serum protein could be considered for these patients.</li></ul>

Method for the determination of glycated hemoglobin

InactiveUS7005273B2Retain and improve accuracySpeed ultimate determinationMicrobiological testing/measurementBiological material analysisIonGlycated hemoglobin
A method of determining the percentage of glycated hemoglobin in a blood sample is disclosed wherein at least one of the assay steps is performed electrochemically. The method includes determining the total amount of hemoglobin in a sample by electrochemically measuring, in an oxygen electroreduction reaction at a cathode, the amount of oxygen in the sample. Because the amount of oxygen dissolved in the sample is known, the total hemoglobin is determined by subtracting the amount of free oxygen from the total oxygen measured, recognizing the fast equilibrium Hb+O2⇄HbO2. This can be followed by determining the amount of glycated hemoglobin in the sample. The cathode reaction is accomplished by contacting the sample with an enzyme, the enzyme being a copper-containing enzyme having four copper ions per active unit. The family of these enzymes includes, for example, laccases and bilirubin oxidases.
Owner:ABBOTT DIABETES CARE INC

Assay device, system and method

A system for treating a blood sample (700) having an analyte of interest comprises a strip (200) having a membrane (218), respective portions (216, 220 and 222, or 300) which are provided for receiving the sample, for lysing cells of the sample to liberate hemoglobin, and for capturing glycated hemoglobin. The latter two portions (220 and 222, or 300) of the membrane are treated with lysing and capture agents, respectively. A portion of the strip (214 or 230 or 240) is provided for holding an eluting agent and for releasing the agent upon a release condition. A system for detecting analyte comprises an optical subsystem (550) that is aligned with the strip to provide a signal corresponding to an amount of analyte, and an electronic subsystem (650) for processing the signal (560) to provide a result, such as an amount or percentage of glycated hemoglobin. To use these systems, the user simply applies a small sample (700) to the membrane (218) and closes a door (10) of the detection system over the strip (200) such that the door triggers the release of the eluting agent. No sample pre-treatment is required. The preferably handheld system (100) is a simple and convenient monitoring tool for the user, such as a diabetic patient who must monitor blood glucose on an on-going basis. While the systems are useful in the monitoring of blood glucose, they may be used for treating a sample other than blood and detecting an analyte other than an analyte in blood.
Owner:ABBOTT DIABETES CARE INC

2-acylaminopropoanol-type glucosylceramide synthase inhibitors

A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
Owner:GENZYME CORP

Reaction cassette for measuring the concentration of glycated hemoglobin and measuring method thereof

A reaction cassette for a glycated hemoglobin meter and a measuring method thereof are provided. The reaction cassette for the glycated hemoglobin meter includes: a first zone receiving a first reagent and a blood sample; a second zone receiving a second reagent; a reaction zone in which the blood sample reacts with the first reagent, or through which the second reagent passes to react with a first blood sample mixture obtained by reacting the blood sample with the first reagent; and a measurement zone measuring an amount of total hemoglobin in the first blood sample mixture, or measuring an amount of glycated hemoglobin in a second blood sample mixture obtained by reacting the first blood sample mixture with the second reagent, wherein the blood sample, the first reagent, and the second reagent move between the reaction zone and the measurement zone according to a rotation angle of the reaction cassette when the reaction cassette is rotated. Therefore, since the reaction cassette reduces the operating time, it is possible to resolve storage and distribution problems of the reaction cassette, which occur when reagents are stored in the reaction cassette.
Owner:OSANG HEALTHCARE CO LTD

Reaction cassette for measuring the concentration of glycated hemoglobin and measuring method thereof

A reaction cassette for a glycated hemoglobin meter and a measuring method thereof are provided. The reaction cassette for the glycated hemoglobin meter includes: a first zone receiving a first reagent and a blood sample; a second zone receiving a second reagent; a reaction zone in which the blood sample reacts with the first reagent, or through which the second reagent passes to react with a first blood sample mixture obtained by reacting the blood sample with the first reagent; and a measurement zone measuring an amount of total hemoglobin in the first blood sample mixture, or measuring an amount of glycated hemoglobin in a second blood sample mixture obtained by reacting the first blood sample mixture with the second reagent, wherein the blood sample, the first reagent, and the second reagent move between the reaction zone and the measurement zone according to a rotation angle of the reaction cassette when the reaction cassette is rotated. Therefore, since the reaction cassette rotates automatically, it is possible to measure the amount of glycated hemoglobin in a blood sample through simple manipulation and reduce a manufacturing time. Furthermore, since reagents are supplied to the reaction cassette from a separate reagent pack, it is possible to resolve storage and distribution problems of the reaction cassette, which occur when reagents are stored in the reaction cassette.
Owner:OSANG HEALTHCARE CO LTD

Kit for determining glycosylated hemoglobin and preparation method thereof

The invention discloses a kit for determining glycosylated hemoglobin and a preparation method thereof. The kit comprises three liquid components a reagent R1, reagent R2 and a reagent R3 that are independently to each other. The reagent R1 consists of: a latex glycine buffer solution, polyethylene glycol-2000, Tween-80, glycerin, bovine serum albumin, and sodium azide, the reagent R2 consists of: a glycine buffer solution, an anti-IgG antibody, an anti-HbA1c antibody, sodium chloride, bovine serum albumin and sodium azide, and the reagent R3 consists of: a hemolysin diluent. The preparation method includes: preparing the reagents according to the component content; mixing a to-be-determined sample with the reagent 3, and using the hemolysin diluents to treat the to-be-determined sample; mixing the treated to-be-determined sample with the reagent R1 and reagent R2 and carry out full reaction; employing a fully automatic biochemical analyser to determine the absorbance difference after reaction; and calculating the concentration of glycosylated hemoglobin in the sample according to an absorbance change value. The kit provided by the invention has the advantages of high accuracy, and convenient operation, etc.
Owner:ANHUI IPROCOM BIOTECH CO LTD

One-step type integrated blood glucose meter

The invention provides a one-step type integrated blood glucose meter comprising a blood glucose meter body, a detecting box in an accommodating groove of the blood glucose meter body and a glycosylated hemoglobin detecting unit. The blood glucose meter body is provided with a control circuit. The detecting box is provided with a blood glucose detecting unit corresponding to a blood collecting port and a guide structure allowing the blood glucose detecting unit provided with a blood collecting needle and a blood glucose test strip to collect blood movably. The blood glucose meter body is provided with a drive mechanism connected to the control circuit, and the drive mechanism is used for driving the blood glucose detecting unit to move by sensitive triggering to allow the blood colleting needle to penetrate the blood collecting port to collect blood and return. A glycosylated hemoglobin detecting position is formed on the surface of the blood glucose meter body through the glycosylated hemoglobin detecting unit. The blood glucose meter body further integrally corresponds to a wireless receiving unit, connected to a wireless emitting unit of a blood glucose sensor planted subcutaneously, and a glucose interpreting unit which is connected to the wireless receiving unit and which is used for dynamically converting and displaying blood glucose values. The blood glucose meter integrates functions of blood glucose detection, dynamic blood glucose monitoring and glycosylated hemoglobin detection, and is small in size and convenient to operate.
Owner:MEDTRUM TECH

Reaction cassette for measuring the concentration of glycated hemoglobin and measuring method thereof

A reaction cassette for a glycated hemoglobin meter and a measuring method thereof are provided. The reaction cassette for the glycated hemoglobin meter includes: a first zone receiving a first reagent and a blood sample; a second zone receiving a second reagent; a reaction zone in which the blood sample reacts with the first reagent, or through which the second reagent passes to react with a first blood sample mixture obtained by reacting the blood sample with the first reagent; and a measurement zone measuring an amount of total hemoglobin in the first blood sample mixture, or measuring an amount of glycated hemoglobin in a second blood sample mixture obtained by reacting the first blood sample mixture with the second reagent, wherein the blood sample, the first reagent, and the second reagent move between the reaction zone and the measurement zone according to a rotation angle of the reaction cassette when the reaction cassette is rotated. Therefore, since the reaction cassette rotates automatically, it is possible to measure the amount of glycated hemoglobin in a blood sample through simple manipulation and reduce a manufacturing time. Furthermore, since reagents are supplied to the reaction cassette from a separate reagent pack, it is possible to resolve storage and distribution problems of the reaction cassette, which occur when reagents are stored in the reaction cassette.
Owner:OSANG HEALTHCARE CO LTD

Methods for assaying percentage of glycated hemoglobin

The invention provides enzymatic methods for direct determination of percentage of glycated hemoglobin in blood samples without the need of a separated measurement of total hemoglobin content in blood samples. The methods utilizes one or two different types of oxidizing agents which selectively oxidize low-molecular weight reducing substances and high-molecular weight (mainly hemoglobin) reducing substances in blood samples, coupled with enzymatic reactions catalyzed by proteases, fructosyl amino acid oxidase. The amount of hydrogen peroxide generated in the reaction is measured for determination of percentage of glycated hemoglobin in blood samples. The invention provides kits for performing the methods of the invention.
Owner:DIAZYME LAB INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products